Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Trial Comparing SHR-1139 Injection With Placebo in Patients With Moderate-to-severe Plaque Psoriasis
Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
Summary
The objective of this study is to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of SHR-1139 injection in patients with moderate to severe plaque psoriasis.
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study Evaluating the Efficacy and Safety of SHR-1139 Injection in Patients With Moderate-to-severe Plaque Psoriasis
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
145
Start Date
2025-03-28
Completion Date
2026-10
Last Updated
2025-07-14
Healthy Volunteers
No
Conditions
Interventions
SHR-1139 Injection
SHR-1139 injection.
SHR-1139 Injection Placebo
SHR-1139 injection placebo.
Locations (1)
Shanghai Dermatology Hospital
Shanghai, Shanghai Municipality, China